Table 2.
The quality and function change of Treg in patients with AIH.
| Patients group (number) | Control group (number) | Patients type | Marker of Treg (detection methods) | Peripheral blood | Liver | Year (Reference) | ||
|---|---|---|---|---|---|---|---|---|
| Number | Function | Number | Function | |||||
| AIH (n = 32) | HC (n = 20) | Adults | CD4+CD25+Foxp3+ (FC) | ↑ | (–) | (–) | (–) | 2018 (83) |
| AIH (n = 42) | HC (n = 15) | (−) | CD4+CD25hiCD127lo/−Foxp3+ (FC) | → | (–) | (–) | (–) | 2017 (31) |
| pAIH (n = 40) | aAIH (n = 45) | Children and adults | CD4+Foxp3+(IF) | (–) | (–) | ↑ | (–) | 2017 (93) |
| AIH (n = 50) | Other chronic liver disease (n = 50) | Children | CD4+Foxp3+ (Tissue immunostaining) | (–) | (–) | ↑ | (–) | 2016 (94) |
| AIH and ASC (n = 43) | HC (n = 22) | Adults and children | CD4+CD25hi/+CD127-(FC) | ↓ | ↓ | (–) | (–) | 2015 (32) |
| AIH (n = 77) | HC (n = 42) or NASH (n = 8) | Adults | CD4+CD25hiCD127loFoxp3+(FC); Foxp3(IHC) | → (vs. HC) | → (vs. HC) | ↑ (vs. NASH) | (–) | 2012 (19) |
| Type 1 AIH (n = 47) | HC (n = 28) | Adults | CD4+CD25hi(FC); Foxp3+(IHC) | ↓ | ↓ | ↓ | (–) | 2010 (95) |
| Type 1 AIH (n = 15) | HC (n = 9) | Adults | CD4+CD25+(FC) | ↑ | ↓ | (–) | (–) | 2008 (96) |
| AIH (n = 25) | HC (n = 15) | Adults and children | Foxp3(PCR) | ↓ | (–) | (–) | (–) | 2006 (18) |
| AIH (n = 28) | HC (n = 15) | Adults and children | CD4+CD25+(FC) | (–) | ↓ | (–) | (–) | 2005 (97) |
| AIH (n = 41) | HC (n = 18) | Adults and children | CD4+CD25+(FC) | ↓ | → | (–) | (–) | 2004 (98) |
AIH, autoimmune hepatitis; pAIH, pediatric AIH; aAIH, adult AIH; ASC, autoimmune hepatitis-sclerosing cholangitis; HC, healthy control; NASH, non-alcoholic hepatitis; FC, flow cytometry; PCR, polymerase chain reaction.